Preserved allografts of dilated saphenous vein for vascular access in hemodialysis: an initial experience.

Annals of Surgery
V A PicconeE Berger

Abstract

Arteriovenous fistulas constructed from preserved (frozen) allograft veins provided vascular access for maintenance hemodialysis in 14 patients with inadequate vasculature for conventional autogenous fistulas. Electromagnetic flows ranged from 200 to 250 cc/min. Dialysis flow of 200 cc/min were accomplished consistently. The allografts were useable for dialysis much earlier than autogenous A-V fistulas. Arteriography demonstrated a wide vasculature channel very suitable for dialysis needles. Allografts seemed superior to bovine heterografts in both patency and susceptibility to infection. Scanning electron microscopy revealed smoother initimal surfaces if the donor received small amounts of heparin systemically while the veins were being removed. Allograft veins appear to be a useful alternative means of vascular access for hemodialysis.

References

Jan 1, 1975·Archives of Surgery·L G ManningC O Hagood
Jan 1, 1973·Transactions - American Society for Artificial Internal Organs·L FloresB S Levowitz
Jan 1, 1973·Transactions - American Society for Artificial Internal Organs·R K Beemer, J F Hayes
Jan 1, 1972·Transactions - American Society for Artificial Internal Organs·J L ChinitzC Swartz
Jun 1, 1971·Annals of Surgery·J L OchsnerG L Leonard
Sep 1, 1966·Archives of Surgery·J W MeadeC V Menendez

❮ Previous
Next ❯

Citations

Sep 1, 1983·World Journal of Surgery·P G Koontz, T S Helling
Aug 1, 1977·Annals of Surgery·L J PerloffC F Barker
Mar 1, 1979·Annals of Surgery·S C AxthelmG M Baur
Nov 25, 2011·Hemodialysis International·Seyed Reza MousaviMohamad Me Akbari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.